Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Page: 107

Published Date: 15 Nov 2024

Category: Service & Software

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market size was valued at US$ 146 million in 2023 and is forecast to a readjusted size of USD 553 million by 2030 with a CAGR of 19.0% during review period.

Live Biotherapeutic Products (LBPs) are biotherapeutic products based on live microorganisms that are intended to treat or prevent disease by modulating the microbiome. These products are usually prepared from specific strains of microorganisms that have potential therapeutic effects, such as improving gut health, boosting the immune system, or reducing inflammation.The rising importance of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating a variety of diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers is the prime factor that propels market growth.CDMOs specializing in these fields have the expertise and infrastructure to support developing and manufacturing these complex therapies, which require specialized equipment and facilities. As a result, pharmaceutical and biotech companies can outsource their production to CDMOs, allowing them to focus on research and development.

This report is a detailed and comprehensive analysis for global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market size and forecasts, in consumption value ($ Million), 2019-2030
Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio), Bacthera (Novonesis+Lonza), Smaltis, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation
Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation
Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Solid Dosage Form
    Liquid Dosage Form

Market segment by Application
    Digestive System Diseases
    Immune System Diseases
    Metabolic Diseases
    Other

Market segment by players, this report covers
    Lallemand Health Solutions
    Wacker Chemie AG
    Biose Industrie
    List Biological Labs, Inc.
    NIZO
    SGS (Quay Pharmaceuticals)
    Assembly Biosciences, Inc.
    Recipharm (Arranta Bio)
    Bacthera (Novonesis+Lonza)
    Smaltis
    Lonza
    vermicon AG

Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, with revenue, gross margin, and global market share of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service from 2019 to 2024.
Chapter 3, the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service.
Chapter 13, to describe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service by Type
        1.3.1 Overview: Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Type in 2023
        1.3.3 Solid Dosage Form
        1.3.4 Liquid Dosage Form
    1.4 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Application
        1.4.1 Overview: Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Digestive System Diseases
        1.4.3 Immune System Diseases
        1.4.4 Metabolic Diseases
        1.4.5 Other
    1.5 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size & Forecast
    1.6 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast by Region
        1.6.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region, (2019-2030)
        1.6.3 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Prospect (2019-2030)
        1.6.4 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Prospect (2019-2030)
        1.6.6 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Prospect (2019-2030)
        1.6.7 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Lallemand Health Solutions
        2.1.1 Lallemand Health Solutions Details
        2.1.2 Lallemand Health Solutions Major Business
        2.1.3 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.1.4 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Lallemand Health Solutions Recent Developments and Future Plans
    2.2 Wacker Chemie AG
        2.2.1 Wacker Chemie AG Details
        2.2.2 Wacker Chemie AG Major Business
        2.2.3 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.2.4 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Wacker Chemie AG Recent Developments and Future Plans
    2.3 Biose Industrie
        2.3.1 Biose Industrie Details
        2.3.2 Biose Industrie Major Business
        2.3.3 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.3.4 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Biose Industrie Recent Developments and Future Plans
    2.4 List Biological Labs, Inc.
        2.4.1 List Biological Labs, Inc. Details
        2.4.2 List Biological Labs, Inc. Major Business
        2.4.3 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.4.4 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 List Biological Labs, Inc. Recent Developments and Future Plans
    2.5 NIZO
        2.5.1 NIZO Details
        2.5.2 NIZO Major Business
        2.5.3 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.5.4 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 NIZO Recent Developments and Future Plans
    2.6 SGS (Quay Pharmaceuticals)
        2.6.1 SGS (Quay Pharmaceuticals) Details
        2.6.2 SGS (Quay Pharmaceuticals) Major Business
        2.6.3 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.6.4 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 SGS (Quay Pharmaceuticals) Recent Developments and Future Plans
    2.7 Assembly Biosciences, Inc.
        2.7.1 Assembly Biosciences, Inc. Details
        2.7.2 Assembly Biosciences, Inc. Major Business
        2.7.3 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.7.4 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Assembly Biosciences, Inc. Recent Developments and Future Plans
    2.8 Recipharm (Arranta Bio)
        2.8.1 Recipharm (Arranta Bio) Details
        2.8.2 Recipharm (Arranta Bio) Major Business
        2.8.3 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.8.4 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Recipharm (Arranta Bio) Recent Developments and Future Plans
    2.9 Bacthera (Novonesis+Lonza)
        2.9.1 Bacthera (Novonesis+Lonza) Details
        2.9.2 Bacthera (Novonesis+Lonza) Major Business
        2.9.3 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.9.4 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Bacthera (Novonesis+Lonza) Recent Developments and Future Plans
    2.10 Smaltis
        2.10.1 Smaltis Details
        2.10.2 Smaltis Major Business
        2.10.3 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.10.4 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Smaltis Recent Developments and Future Plans
    2.11 Lonza
        2.11.1 Lonza Details
        2.11.2 Lonza Major Business
        2.11.3 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.11.4 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 Lonza Recent Developments and Future Plans
    2.12 vermicon AG
        2.12.1 vermicon AG Details
        2.12.2 vermicon AG Major Business
        2.12.3 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
        2.12.4 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.12.5 vermicon AG Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service by Company Revenue
        3.2.2 Top 3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Market Share in 2023
        3.2.3 Top 6 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Market Share in 2023
    3.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Overall Company Footprint Analysis
        3.3.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Region Footprint
        3.3.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Company Product Type Footprint
        3.3.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Application (2019-2024)
    5.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2019-2030)
    6.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2019-2030)
    6.3 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country
        6.3.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2019-2030)
        6.3.2 United States Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        6.3.3 Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        6.3.4 Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2019-2030)
    7.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2019-2030)
    7.3 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country
        7.3.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2019-2030)
        7.3.2 Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        7.3.3 France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        7.3.5 Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        7.3.6 Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region
        8.3.1 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Region (2019-2030)
        8.3.2 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        8.3.3 Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        8.3.4 South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        8.3.5 India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        8.3.7 Australia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2019-2030)
    9.2 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2019-2030)
    9.3 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country
        9.3.1 South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2019-2030)
        9.3.2 Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        9.3.3 Argentina Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country
        10.3.1 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2019-2030)
        10.3.2 Turkey Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)
        10.3.4 UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Drivers
    11.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Restraints
    11.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Chain
    12.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Upstream Analysis
    12.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Midstream Analysis
    12.4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 2. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 3. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Region (2019-2024) & (USD Million)
 Table 4. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Region (2025-2030) & (USD Million)
 Table 5. Lallemand Health Solutions Company Information, Head Office, and Major Competitors
 Table 6. Lallemand Health Solutions Major Business
 Table 7. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 8. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 9. Lallemand Health Solutions Recent Developments and Future Plans
 Table 10. Wacker Chemie AG Company Information, Head Office, and Major Competitors
 Table 11. Wacker Chemie AG Major Business
 Table 12. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 13. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 14. Wacker Chemie AG Recent Developments and Future Plans
 Table 15. Biose Industrie Company Information, Head Office, and Major Competitors
 Table 16. Biose Industrie Major Business
 Table 17. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 18. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 19. List Biological Labs, Inc. Company Information, Head Office, and Major Competitors
 Table 20. List Biological Labs, Inc. Major Business
 Table 21. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 22. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 23. List Biological Labs, Inc. Recent Developments and Future Plans
 Table 24. NIZO Company Information, Head Office, and Major Competitors
 Table 25. NIZO Major Business
 Table 26. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 27. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 28. NIZO Recent Developments and Future Plans
 Table 29. SGS (Quay Pharmaceuticals) Company Information, Head Office, and Major Competitors
 Table 30. SGS (Quay Pharmaceuticals) Major Business
 Table 31. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 32. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 33. SGS (Quay Pharmaceuticals) Recent Developments and Future Plans
 Table 34. Assembly Biosciences, Inc. Company Information, Head Office, and Major Competitors
 Table 35. Assembly Biosciences, Inc. Major Business
 Table 36. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 37. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 38. Assembly Biosciences, Inc. Recent Developments and Future Plans
 Table 39. Recipharm (Arranta Bio) Company Information, Head Office, and Major Competitors
 Table 40. Recipharm (Arranta Bio) Major Business
 Table 41. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 42. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 43. Recipharm (Arranta Bio) Recent Developments and Future Plans
 Table 44. Bacthera (Novonesis+Lonza) Company Information, Head Office, and Major Competitors
 Table 45. Bacthera (Novonesis+Lonza) Major Business
 Table 46. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 47. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 48. Bacthera (Novonesis+Lonza) Recent Developments and Future Plans
 Table 49. Smaltis Company Information, Head Office, and Major Competitors
 Table 50. Smaltis Major Business
 Table 51. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 52. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 53. Smaltis Recent Developments and Future Plans
 Table 54. Lonza Company Information, Head Office, and Major Competitors
 Table 55. Lonza Major Business
 Table 56. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 57. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 58. Lonza Recent Developments and Future Plans
 Table 59. vermicon AG Company Information, Head Office, and Major Competitors
 Table 60. vermicon AG Major Business
 Table 61. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product and Solutions
 Table 62. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 63. vermicon AG Recent Developments and Future Plans
 Table 64. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (USD Million) by Players (2019-2024)
 Table 65. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Players (2019-2024)
 Table 66. Breakdown of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3)
 Table 67. Market Position of Players in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
 Table 68. Head Office of Key Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players
 Table 69. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Company Product Type Footprint
 Table 70. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market: Company Product Application Footprint
 Table 71. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service New Market Entrants and Barriers to Market Entry
 Table 72. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Mergers, Acquisition, Agreements, and Collaborations
 Table 73. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (USD Million) by Type (2019-2024)
 Table 74. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Share by Type (2019-2024)
 Table 75. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Forecast by Type (2025-2030)
 Table 76. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2019-2024)
 Table 77. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Forecast by Application (2025-2030)
 Table 78. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2019-2024) & (USD Million)
 Table 79. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2025-2030) & (USD Million)
 Table 80. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2019-2024) & (USD Million)
 Table 81. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2025-2030) & (USD Million)
 Table 82. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2019-2024) & (USD Million)
 Table 83. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2025-2030) & (USD Million)
 Table 84. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2019-2024) & (USD Million)
 Table 85. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2025-2030) & (USD Million)
 Table 86. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2019-2024) & (USD Million)
 Table 87. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2025-2030) & (USD Million)
 Table 88. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2019-2024) & (USD Million)
 Table 89. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2025-2030) & (USD Million)
 Table 90. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2019-2024) & (USD Million)
 Table 91. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2025-2030) & (USD Million)
 Table 92. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2019-2024) & (USD Million)
 Table 93. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2025-2030) & (USD Million)
 Table 94. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Region (2019-2024) & (USD Million)
 Table 95. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Region (2025-2030) & (USD Million)
 Table 96. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2019-2024) & (USD Million)
 Table 97. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2025-2030) & (USD Million)
 Table 98. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2019-2024) & (USD Million)
 Table 99. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2025-2030) & (USD Million)
 Table 100. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2019-2024) & (USD Million)
 Table 101. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2025-2030) & (USD Million)
 Table 102. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2019-2024) & (USD Million)
 Table 103. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type (2025-2030) & (USD Million)
 Table 104. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2019-2024) & (USD Million)
 Table 105. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application (2025-2030) & (USD Million)
 Table 106. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2019-2024) & (USD Million)
 Table 107. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Country (2025-2030) & (USD Million)
 Table 108. Global Key Players of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Upstream (Raw Materials)
 Table 109. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Typical Customers


List of Figures
 Figure 1. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Picture
 Figure 2. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Figure 3. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Type in 2023
 Figure 4. Solid Dosage Form
 Figure 5. Liquid Dosage Form
 Figure 6. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 7. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Application in 2023
 Figure 8. Digestive System Diseases Picture
 Figure 9. Immune System Diseases Picture
 Figure 10. Metabolic Diseases Picture
 Figure 11. Other Picture
 Figure 12. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value, (USD Million): 2019 & 2023 & 2030
 Figure 13. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value and Forecast (2019-2030) & (USD Million)
 Figure 14. Global Market Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (USD Million) Comparison by Region (2019 VS 2023 VS 2030)
 Figure 15. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Region (2019-2030)
 Figure 16. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Region in 2023
 Figure 17. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 18. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 19. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 20. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 21. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 22. Company Three Recent Developments and Future Plans
 Figure 23. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Share by Players in 2023
 Figure 24. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2023
 Figure 25. Market Share of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service by Player Revenue in 2023
 Figure 26. Top 3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Market Share in 2023
 Figure 27. Top 6 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Market Share in 2023
 Figure 28. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Share by Type (2019-2024)
 Figure 29. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share Forecast by Type (2025-2030)
 Figure 30. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Share by Application (2019-2024)
 Figure 31. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share Forecast by Application (2025-2030)
 Figure 32. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Type (2019-2030)
 Figure 33. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Application (2019-2030)
 Figure 34. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Country (2019-2030)
 Figure 35. United States Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 36. Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 37. Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 38. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Type (2019-2030)
 Figure 39. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Application (2019-2030)
 Figure 40. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Country (2019-2030)
 Figure 41. Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 42. France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 43. United Kingdom Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 44. Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 45. Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 46. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Type (2019-2030)
 Figure 47. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Application (2019-2030)
 Figure 48. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Region (2019-2030)
 Figure 49. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 50. Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 51. South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 52. India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 53. Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 54. Australia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 55. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Type (2019-2030)
 Figure 56. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Application (2019-2030)
 Figure 57. South America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Country (2019-2030)
 Figure 58. Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 59. Argentina Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 60. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Type (2019-2030)
 Figure 61. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Application (2019-2030)
 Figure 62. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value Market Share by Country (2019-2030)
 Figure 63. Turkey Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 64. Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 65. UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 66. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Drivers
 Figure 67. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Restraints
 Figure 68. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Trends
 Figure 69. Porters Five Forces Analysis
 Figure 70. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industrial Chain
 Figure 71. Methodology
 Figure 72. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Lallemand Health Solutions
Wacker Chemie AG
Biose Industrie
List Biological Labs, Inc.
NIZO
SGS (Quay Pharmaceuticals)
Assembly Biosciences, Inc.
Recipharm (Arranta Bio)
Bacthera (Novonesis+Lonza)
Smaltis
Lonza
vermicon AG

Related Reports

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Supply, Demand and Key Producers, 2024-2030

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Supply, Demand and Key Producers, 2024-2030

date 15 Nov 2024

date Service & Software

The global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market size is expected to reach $ 553 million by 2030, rising at a market growth of 19.0% CAGR during the forecast period (2024-2030).

Product Tags

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service

soil fertility

Image High Dynamic

Building Energy Modeling

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>